Results 71 to 80 of about 57,420 (217)
THE "NEW" DRUG CLASSES IN THE TREATMENT OF CHRONIC HEART FAILURE AND THEIR EVIDENCE BASE
A comparison of ivabradine and omega-3 polyunsaturated fatty acids, drugs with principally different mechanisms of action, is presented in patients with chronic heart failure (CHF) on the base of GISSI-HF and SHIFT trails results.
S. N. Tereshchenko +3 more
doaj +1 more source
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley +1 more source
The review aimed to illustrate the structure, role and effects of omega-3 polyunsaturated fatty acids (omega-3 PUFAs) in combination with acetylsalicylic acid (aspirin, ASA) in various clinical cases.
Zajac-Grabiec Anna +2 more
doaj +1 more source
ABSTRACT The effects of fish oil supplementation on omega‐3 (n‐3) polyunsaturated fatty acids, particularly intermediates between eicosapentaenoic acid (EPA, 20:5n‐3) and docosahexaenoic acid (DHA, 22:6n‐3), that may provide valuable metabolic information, have not been fully characterized in older populations.
David C. R. Ku +4 more
wiley +1 more source
Nutrients, including vital organic compounds, vary in availability across ecosystems, with the potential to act as a source of selection for traits that increase nutrient acquisition and biosynthesis. Compared to freshwaters, marine ecosystems are richer in the omega‐3 long‐chain polyunsaturated fatty acid (n‐3 LC‐PUFA) docosahexaenoic acid (DHA ...
Cornelia W. Twining +12 more
wiley +1 more source
This study found that the metabolomic signature of umbilical venous cord blood in congenital heart disease (CHD) differs from that of healthy monozygotic (MZ) co‐twins. Dysregulation of metabolic pathways like glucose, lipid, and amino acid metabolism, along with altered metabolites, helps understand CHD predisposition.
Fang Xiang +6 more
wiley +1 more source
When Fat Goes Astray: Your Liver and Pancreas Get Into Trouble
Metabolic dysfunction‐associated steatotic liver disease (MASLD) and intrapancreatic fat deposition (IPFD) are both common manifestations of ectopic fat accumulation. Although they share multiple risk factors, they also show notable differences in pathological features, standardization of diagnosis, and research maturity.
Yuying Chen +5 more
wiley +1 more source
Phytochemicals in MASLD: A Focused Review of Gut Microbiome‐Linked Mechanisms
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as a major global health burden, yet effective pharmacological options remain limited. Recent advances highlight the gut microbiome as a key modulator of liver metabolism, inflammation, and fibrosis, making it a promising therapeutic target.
Jeong In Seo, Su Min Kim, Hye Hyun Yoo
wiley +1 more source
The full editable vector source file of this graphical abstract is uploaded as a supplementary EPS file for typesetting. All elements are copyright‐free. Abstract Age‐related ocular diseases (ARODs), including cataract, primary open‐angle glaucoma (POAG), and age‐related macular degeneration (AMD), are leading causes of vision impairment and exhibit ...
Linge Jian +6 more
wiley +1 more source
The active folates and omega-3 polyunsaturated fatty acids (omega-3 PUFAs) effects are often considered separately. At the same time, a pharmacodynamic interaction exists between those essential micronutrients in order to support the full development of ...
O A Gromova, I Yu Torshin, O A Limanova
doaj

